Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hwa-Jung Kim has a total of 501 co-authors. Here are the top co-authors by number of shared publications:

  • Jeong-Kyu Park

    Department of Microbiology and Research Institute for Medical Sciences, College of Medicine, Chungnam National University, Daejeon, Korea

    45 shared publications
  • Chang-Hwa Song

    Department of Medical Science, College of Medicine Chungnam National University Daejeon Republic of Korea

    36 shared publications
  • Eun-Kyeong Jo

    Department of Microbiology, College of Medicine, Chungnam National University, Daejeon, Republic of Korea

    34 shared publications
  • Sung Jae Shin

    Department of Microbiology, Institute for Immunology and Immunological Disease, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, Republic of Korea

    29 shared publications
  • Han-Gyu Choi

    Department of Microbiology and Medical Science, College of Medicine, Chungnam National University, 266 Munhwa-ro, Jung-gu, Daejeon 35015, South Korea; Translational Immunology Institute, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, South Korea

    21 shared publications
  • Yong Woo Back

    R&D Center, Myco-Rapha Inc., Daejeon 35015, South Korea

    19 shared publications

Latest Publications

  • Open Access

    Integrated Computational Pipeline Combining Metabolomics and Network Pharmacology for Bioactive Scaffold Discovery: Application to Antarctic Moss Chorisodontium aciphyllum

    by Hirotake Yamaguchi, Hye‐Soo Park, Ryoichi Yamada, Hwa‐Jung Kim, Ui Joung Youn, Jun Hyuck Lee, Tae‐Jin Oh

    Discovering lead compounds from complex natural matrices traditionally requires resource‐intensive isolation steps. Integrating computational biology with untargeted metabolomics offers a more efficient alternative for rapid target prediction and screening. Here, we present a computational pipeline combining LC–MS/MS metabolomics, network pharmacology, and molecular docking to identify bioactive scaffolds. We applied this approach to the methanolic extract of the Antarctic moss Chorisodontium aciphyllum as a model matrix. Profiling the bioactive fraction (Fr.3) identified 17 secondary metabolites, primarily featuring fatty acid and steroidal scaffolds. Network pharmacology and functional annotation predicted ERBB2 and AKT1 as key protein targets for anti‐lung cancer activity. Molecular docking supported these predictions, showing that steroidal and secosteroidal compounds such as 5α‐ergosta‐7,22‐diene‐3β,5‐diol and 25‐hydroxyvitamin D2 exhibit high binding affinities to these targets. As a preliminary in vitro validation of the computationally predicted pathways, we found that Fr.3 significantly increased intracellular reactive oxygen species (ROS) levels and induced apoptosis‐mediated cell death in LLC1 murine lung cancer cells (IC 50 ≈ 45.79 µg/mL). Our findings demonstrate that combining untargeted metabolomics with computational analysis can effectively streamline the discovery of therapeutic leads from uncharacterized natural extracts.

  • Mycobacterial fusion protein REA eliciting anti-tumor activity through activation of innate immunity

    by Thuy An Pham, Seunga Choi, Sintayehu Kebede Gurmessa, Han-Gyu Choi, Yeo-Jin Son, Yong Woo Back, Hye-Soo Park, In-Taek Jang, Chae-Bok Lee, Ki-Won Shin, et al.

  • Open Access

    IFN-γ and IL-17 elicit synergistic anti-mycobacterial responses by inhibiting coronin-1A retention

    by Hye-Soo Park, Thuy An Pham, ZongYou Jiang, Seunga Choi, Yong Woo Back, In-Taek Jang, Ki Won Shin, Yeo-Jin Son, Han-Gyu Choi, Hwa-Jung Kim

    CD4+IFN-γ+IL-17+ T cells and their secreted cytokines play a critical role in the anti-mycobacterial response. However, the underlying synergistic mechanism of IFN-γ and IL-17 is little known. This study demonstrates that the downregulation of coronin-1A retention on the phagosome is a synergistic pathway for IFN-γ and IL-17 that kills Mycobacterium tuberculosis (Mtb) in macrophages. IL-17 alone does not play a role in intracellular Mtb killing but potentiates the anti-mycobactericidal pathway of IFN-γ. Co-treatment of IFN-γ/IL-17 inhibited phosphorylation of STAT3, induced LRG47 expression, and reduced retention of coronin-1A on phagosome, thereby eliciting phagolysosomal fusion and bacterial killing, which was proved through response analysis of IFN-γ/IL-17 in Mtb-infected macrophages transfected with small interfering RNA of coro1a, lrg47, or stat1. Determination of adjunctive therapeutic effect of IFN-γ, IL-17, or both with anti-mycobacterial drugs showed that the bacterial load in the tissue of mice co-treated with IFN-γ/IL-17, even at 1 ng/mL concentration each, was more rapidly reduced compared to those of IFN-γ injection or chemotherapy alone. It inhibited the re-growth after treatment termination. Our results shed new light on the synergistic mechanisms of IFN-γ/IL-17 for anti-mycobacterial responses, which might be targeted as an adjunctive chemotherapeutic method against tuberculosis.


  • Open Access

    Endogenous hepcidin plays an essential role in Mycobacterium tuberculosis Rv1876 antigen-induced antimicrobial activity in macrophages

    by Hye-Soo Park, Han-Gyu Choi, In-Taek Jang, Thuy An Pham, Zongyou Jiang, Yeo-Jin Son, Kwangwook Kim, Hwa-Jung Kim

    Tuberculosis (TB) is one of the most prevalent infectious diseases worldwide. However, few molecules related to bacterial killing within T cell-induced macrophages are known; therefore, elucidating host responses against bacterial components is critical for developing strategies to treat TB. This study investigated the anti-mycobacterial responses induced by Mycobacterium tuberculosis (Mtb) Rv1876 (bacterioferritin A). Rv1876 effectively activated macrophages; however, the protein itself did not elicit bacterial killing. When co-cultured with T cells (Rv1876-T cell), Mtb growth was substantially inhibited in Rv1876-activated macrophages. Rv1876-T cells enhanced endogenous hepcidin expression, an antimicrobial peptide, in Mtb-infected macrophages, which was co-localized adjacent to bacteria-containing phagosomes and directly interacted with them. Other major mycobacterial proteins and bacterioferritin B (Rv3841) did not induce hepcidin in Mtb-infected macrophages, irrespective of T cell involvement. These findings suggest that endogenous hepcidin induced by Rv1876-T cells may be a host bactericidal response and a promising target for host-directed therapies.


  • Open Access

    Novel fusion protein REA induces robust prime protection against tuberculosis in mice

    by Sintayehu Kebede Gurmessa, Han-Gyu Choi, Yong Woo Back, Zongyou Jiang, Thuy An Pham, Seunga Choi, Hwa-Jung Kim

    While many novel candidates for tuberculosis vaccines are presently undergoing pre-clinical or clinical trials, none of them have been able to eliminate infection entirely. In this study, we engineered a potent chimeric protein vaccine candidate, Rv2299cD2D3-ESAT-6-Ag85B (REA), which induced Th1 and Th17 responses via dendritic cell maturation. REA-activated macrophages operated the killing mechanisms of Mycobacterium tuberculosis (MTB), such as phagosomal maturation and phagolysosome fusion, through the (PI3K)–p38 MAPK-Ca2+-NADPH oxidase pathway. Dendritic cells and macrophages activated by REA elicited synergistic anti-mycobacterial responses. Notably, REA-immunized mice suppressed MTB growth to undetectable levels at 16 weeks post-infection, which was supported by gross and pathologic findings and acid-fast staining of the lung tissues, and maintained antigen-specific multifunctional IFN-γ+IL-2+TNF-α CD4+ T and long-lasting T cells producing cytokines in the tissues. Our findings suggest that REA is an outstanding prime prophylactic vaccine candidate against tuberculosis.


  • Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases

    by Tam Doan Nguyen, Ji-Ae Choi, Hee-Jong Lim, Chong Hak Chae, Junghwan Lee, Sang-Hun Son, Jaewhan Kim, Doyi Son, Hwa-Jung Kim, Chang-Hwa Song

    Acetohydroxyacid synthase (AHAS), exclusively present in microorganisms and plants, is a promising target for several herbicides due to its catalytic role in the branched-chain amino acid biosynthetic pathway. Previous studies have shown that K13787, a pyrazolopyrimidine sulfonamide AHAS inhibitor, was moderately effective against pulmonary infection caused by M. tuberculosis and nontuberculous mycobacteria (NTM). In this study, we synthesized various structural derivatives of K13787 based on the molecular docking studies and assessed their MICs against mycobacteria species. Among the synthetic compounds screened, K13787, along with KNT2077 and KNT2099, exhibited inhibitory efficacy against M. avium and M. abscessus, including CLR-resistant NTM species. Notably, these compounds displayed a synergistic effect (FIC ≤ 0.5) when combined with CLR against M. avium and M. abscessus. Our findings suggest that these newly identified AHAS-targeted compounds hold promise as lead candidates for novel antimycobacterial agents against NTM infections. Considering the structure-activity relationship, K13787, KNT2077, and KTN2099 emerge as potential treatments for NTM species.


  • Open Access

    Enhancing antitumor immunity in Lewis lung cancer through plasma-treated medium-induced activation of dendritic cells

    by Chae Bok Lee, Hei Gwon Choi, Sintayehu Kebede Gurmessa, In-Taek Jang, Naresh Kumar, Zongyou Jiang, Nagendra Kumar Kaushik, Hwa-Jung Kim

    Recently, atmospheric non-thermal plasma jet-treated medium (PTM) has been recognized as a novel strategy in cancer therapy and lymphocyte activation. However, PTM has limitations in inducing a robust antitumor-immune response. This study demonstrated that PTM treatment inhibited tumor progression by activating dendritic cells (DCs). In this study, we investigated the effects of PTM on selective cytotoxicity and intracellular reactive oxygen species (ROS) generation and oxidative stress-mediated signaling (e.g., glutathione peroxidase, catalase) using respective fluorescence probes in Lewis lung cancer (LLC) cells. Then, the PTM affects the expression of interferon-gamma (IFN)-γ-induced programmed death-ligand 1 (PD-L1) and inhibition of signal transducer and activator of transcription 1 (STAT1) in LLC cells using immunoblotting. Additionally, PTM effects on the tumor cell’s death and activation of DCs were done by co-culturing DCs with or without tumor cells. Further, a mouse model was used to evaluate the synergistic antitumor effects of PTM and DCs where tumors are grown under the skin. PTM-exposed tumor cells increase intracellular superoxide production, enhancing ROS generation and leading to cancer immunogenic cell death. In addition, PTM suppresses IFN-γ-induced PD-L1 expression and STAT1 activation in tumor cells. The activation of DCs induced by PTM is downregulated when these cells are co-cultured with tumor cells. In vivo, intraperitoneal injection of PTM-activated DCs, as a synergistic agent to intertumoral PTM treatment, led to increased CD4+ and CD8+ T cell infiltration into the tumor and spleen and eventually decreased tumor growth. Overall, this research introduces a promising avenue for improving lung cancer treatment using PTM to stimulate an immune response and induce cell death in tumor cells. Further studies will be essential to validate these findings and explore clinical applications.


  • Open Access

    BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice

    by Kee Woong Kwon, Han-Gyu Choi, Kwang Sung Kim, Shin Ae Park, Hwa-Jung Kim, Sung Jae Shin

    The quest for effective and enhanced multiantigenic tuberculosis (TB) subunit vaccine necessitates the induction of a protective pathogen-specific immune response while circumventing detrimental inflammation within the lung milieu. In line with this goal, we engineered a modified iteration of the quadrivalent vaccine, namely HSP90-ESAT-6-HspX-RipA (HEHR), which was coupled with the TLR4 adjuvant, CIA09A. The ensuing formulation was subjected to comprehensive assessment to gauge its protective efficacy against the hypervirulent Mycobacterium tuberculosis (Mtb) Haarlem clinical strain M2, following a BCG-prime boost regimen. Regardless of vaccination route, both intramuscular and subcutaneous administration with the HEHR vaccine exhibited remarkable protective efficacy in significantly reducing the Mtb bacterial burden and pulmonary inflammation. This underscores its notably superior protective potential compared to the BCG vaccine alone or a former prototype, the HSP90-E6 subunit vaccine. In addition, this superior protective efficacy was confirmed when testing a tag-free version of the HEHR vaccine. Furthermore, the protective immune determinant, represented by durable antigen-specific CD4+IFN-γ+IL-17A+ T-cells expressing a CXCR3+KLRG1- cell surface phenotype in the lung, was robustly induced in HEHR-boosted mice at 12 weeks post-challenge. Collectively, our data suggest that the BCG-prime HEHR boost vaccine regimen conferred improved and long-term protection against hypervirulent Mtb strain with robust antigen-specific Th1/Th17 responses.


  • Open Access

    A Structural View at Vaccine Development against M. tuberculosis

    by Maria Romano, Flavia Squeglia, Eliza Kramarska, Giovanni Barra, Han-Gyu Choi, Hwa-Jung Kim, Alessia Ruggiero, Rita Berisio

    Tuberculosis (TB) is still the leading global cause of death from an infectious bacterial agent. Limiting tuberculosis epidemic spread is therefore an urgent global public health priority. As stated by the WHO, to stop the spread of the disease we need a new vaccine, with better coverage than the current Mycobacterium bovis BCG vaccine. This vaccine was first used in 1921 and, since then, there are still no new licensed tuberculosis vaccines. However, there is extremely active research in the field, with a steep acceleration in the past decades, due to the advance of technologies and more rational vaccine design strategies. This review aims to gather latest updates in vaccine development in the various clinical phases and to underline the contribution of Structural Vaccinology (SV) to the development of safer and effective antigens. In particular, SV and the development of vaccine adjuvants is making the use of subunit vaccines, which are the safest albeit the less antigenic ones, an achievable goal. Indeed, subunit vaccines overcome safety concerns but need to be rationally re-engineered to enhance their immunostimulating effects. The larger availability of antigen structural information as well as a better understanding of the complex host immune response to TB infection is a strong premise for a further acceleration of TB vaccine development.